Clinical Trials Logo

Filter by:
NCT ID: NCT05780190 Recruiting - Clinical trials for To Evaluate the Clinical Efficacy and Safety of the New ALSS

Clinical Observation of CABA System in the Treatment of End-stage Liver Disease With Inflammation

Start date: March 10, 2023
Phase: Phase 4
Study type: Interventional

End-stage liver disease (ESLD) refers to the late stage of liver disease caused by various chronic liver damage. ESLD is an important cause of global incidence rate and mortality, which has a significant impact on the health care system. ESLD is associated with various types of immune dysfunction. The artificial liver support system (ALSS) is an extracorporeal support system that temporarily and partially replaces the partial function of the liver. Its treatment mechanism is to remove all kinds of harmful substances, supplement essential substances, improve the internal environment, create conditions for hepatocyte regeneration and liver function recovery, or use it as a symptomatic support treatment method during the perioperative period of liver transplantation. In this study, we plan to use BS330 for plasma bilirubin adsorption. On this basis, we will add a CA280 cytokine adsorption column to establish a new artificial liver combination model CABA for the immune inflammatory damage mechanism of liver failure.

NCT ID: NCT05779995 Recruiting - RSV Infection Clinical Trials

A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV

Start date: April 20, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled Phase Ib/IIa study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of XW001 inhalation in children with RSV infection in China

NCT ID: NCT05779917 Recruiting - Pancreas Cancer Clinical Trials

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

Start date: March 10, 2023
Phase: Phase 1
Study type: Interventional

The second generation of mesothelin targeted CAR-T cells that secret a fusion protein of IL21 and scfv against PD1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-T cells for immunotherapy of human cancer patients with Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the Mesothelin-CAR-T cell immunotherapy on human cancers will firstly be evaluated.

NCT ID: NCT05779644 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Start date: February 23, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.

NCT ID: NCT05779579 Recruiting - COVID-19 Clinical Trials

Study of HS-10517 in Chinese Adult Participants

Start date: February 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and primary efficacy of HS-10517 in Chinese adult participants.

NCT ID: NCT05779514 Recruiting - Tumour Clinical Trials

Effect of Mirabegron on Promoting Brown Adipose Tissue Activation

Start date: August 18, 2022
Phase: N/A
Study type: Interventional

In previous preclinical studies, our group found that Mirabegron, a clinical drug, could activate brown adipose tissue and inhibit tumor growth in tumour-bearing mice.Investigators look forward to further evaluating the effect of Mirabegron-mediated brown adipose tissue activation, so as to provide new drug applications for clinical cancer prevention and treatment

NCT ID: NCT05779215 Recruiting - Clinical trials for Acute Ischemic Stroke

Registry of Acute Ischemic Stroke With Large- or Medium-vessel Occlusion

LOMEVO
Start date: April 25, 2023
Phase:
Study type: Observational [Patient Registry]

This study is designed to observe the treatment options in real-world clinical practice as well as the safety and efficacy of different treatment strategies.

NCT ID: NCT05779176 Not yet recruiting - Stroke, Ischemic Clinical Trials

Safety and Efficacy of Therapeutic Hypothermia in Acute Ischemic Stroke

THIS
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Therapeutic hypothermia (TH) in stroke has demonstrated robust neuroprotection in animals especially after ischemia-reperfusion injury, but its safety and efficacy remain controversial. The investigators propose this trial to study the clinical and radiological effects of therapeutic hypothermia in acute ischemic stroke patients treated with intravascular thrombectomy (IVT).

NCT ID: NCT05779163 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

Start date: April 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.

NCT ID: NCT05779150 Recruiting - Pruritus Clinical Trials

Efficacy of CeraVe® Moisturizing Cream on Skin Pruritus in Elderly Patients

Start date: February 26, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the CeraVe® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus. The main questions it aims to answer are: type of study: clinical trial participant population:in patients with chronic elderly pruritus [question 1] Evaluate the CeraVe® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus, including improvements of redness, dryness/squamation, itching, burning, tingling, tightness and other factors. [question 2] Evaluate the tolerance of CeraVe® Moisturising Cream. [question 3] Evaluate the product experience of patients who were utilizing CeraVe® Moisturising Cream. This trial utilizing simple randomization, the left and right calves of paticipants were randomly divided into test side(applicating CeraVe® Moisturising Cream ) and control side (applicating Standard Cream)according to random number representation. Grouping results were double-blinded.